Harvey Investment Co. LLC Raises Position in STERIS plc $STE

Harvey Investment Co. LLC grew its holdings in shares of STERIS plc (NYSE:STE) by 17.1% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 93,105 shares of the medical equipment provider’s stock after acquiring an additional 13,580 shares during the period. STERIS comprises approximately 2.5% of Harvey Investment Co. LLC’s holdings, making the stock its 16th largest position. Harvey Investment Co. LLC owned about 0.09% of STERIS worth $23,038,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of STE. Vanguard Group Inc. grew its holdings in STERIS by 1.7% during the second quarter. Vanguard Group Inc. now owns 12,163,128 shares of the medical equipment provider’s stock valued at $2,921,827,000 after purchasing an additional 205,276 shares during the period. State Street Corp raised its stake in shares of STERIS by 2.4% in the second quarter. State Street Corp now owns 4,188,103 shares of the medical equipment provider’s stock worth $1,006,069,000 after buying an additional 98,220 shares during the period. Geode Capital Management LLC lifted its position in shares of STERIS by 1.9% during the 2nd quarter. Geode Capital Management LLC now owns 2,479,108 shares of the medical equipment provider’s stock valued at $592,980,000 after buying an additional 46,859 shares in the last quarter. Orbis Allan Gray Ltd grew its stake in shares of STERIS by 36.0% during the 2nd quarter. Orbis Allan Gray Ltd now owns 2,100,099 shares of the medical equipment provider’s stock valued at $504,486,000 after acquiring an additional 556,088 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in STERIS by 55.2% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,520,479 shares of the medical equipment provider’s stock worth $344,617,000 after acquiring an additional 540,999 shares in the last quarter. 94.69% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the stock. Wall Street Zen raised shares of STERIS from a “buy” rating to a “strong-buy” rating in a report on Sunday, September 14th. Weiss Ratings restated a “buy (b)” rating on shares of STERIS in a research report on Tuesday, October 14th. Seven research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $273.50.

Insider Buying and Selling at STERIS

In related news, VP John Adam Zangerle sold 15,000 shares of the business’s stock in a transaction dated Tuesday, November 11th. The stock was sold at an average price of $265.14, for a total value of $3,977,100.00. Following the sale, the vice president directly owned 33,669 shares in the company, valued at approximately $8,926,998.66. The trade was a 30.82% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Julia Madsen sold 5,008 shares of the stock in a transaction that occurred on Friday, November 21st. The shares were sold at an average price of $262.00, for a total value of $1,312,096.00. Following the transaction, the vice president directly owned 10,710 shares of the company’s stock, valued at approximately $2,806,020. The trade was a 31.86% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 25,044 shares of company stock valued at $6,586,218 in the last 90 days. Insiders own 1.07% of the company’s stock.

STERIS Trading Down 1.4%

STE stock opened at $250.07 on Monday. The company has a debt-to-equity ratio of 0.27, a current ratio of 2.37 and a quick ratio of 1.63. STERIS plc has a 1-year low of $200.98 and a 1-year high of $268.60. The business has a 50 day simple moving average of $255.47 and a two-hundred day simple moving average of $245.11. The company has a market capitalization of $24.54 billion, a price-to-earnings ratio of 35.93 and a beta of 1.03.

STERIS (NYSE:STE) last released its quarterly earnings data on Wednesday, November 5th. The medical equipment provider reported $2.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.38 by $0.09. STERIS had a net margin of 12.07% and a return on equity of 14.43%. The firm had revenue of $1.46 billion for the quarter, compared to analysts’ expectations of $1.43 billion. During the same quarter last year, the business posted $2.14 earnings per share. STERIS has set its FY 2026 guidance at 10.150-10.30 EPS. Research analysts anticipate that STERIS plc will post 9.08 EPS for the current fiscal year.

STERIS Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Thursday, December 18th. Shareholders of record on Tuesday, November 18th were paid a $0.63 dividend. The ex-dividend date was Tuesday, November 18th. This represents a $2.52 annualized dividend and a yield of 1.0%. STERIS’s payout ratio is presently 36.21%.

STERIS Company Profile

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.